Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 7, 2014, Pages 808-817

  Becker, Mike O ^a,b   Kill, Angela ^a,b   Kutsche, Marissa ^a,b   Guenther, Jeannine ^a,b   Rose, Angelika ^a,b   Tabeling, Christoph ^a   Witzenrath, Martin ^a   Kühl, Anja A ^c   Heidecke, Harald ^d   Ghofrani, Hossein A ^e,f   Tiede, Henning ^e,f   Schermuly, Ralph T ^e,f   Nickel, Nils ^g   Hoeper, Marius M ^g   Lukitsch, Ivo ^a   Gollasch, Maik ^a   Kuebler, Wolfgang M ^a,h   Bock, Sebastian ^a,b   Burmester, Gerd R ^a,b   Dragun, Duska ^a   Riemekasten, Gabriela ^a,b   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b A Leibniz Institute   (Germany)

^c Infectious Diseases and Rheumatology   (Germany)

^d CellTrend GmbH   (Germany)

^e UNIVERSITY HOSPITAL GIESSEN   (Germany)

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Angiotensin receptor type 1; Autoantibodies; Endothelin receptor type A; Pulmonary arterial hypertension; Systemic sclerosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR TYPE 1; AUTOANTIBODY; CALCIUM; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR TYPE A; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN TARGETING; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS; ANIMAL; BLOOD; C57BL MOUSE; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MIDDLE AGED; MYOGRAPHY; PROCEDURES; PULMONARY ARTERY; RAT; SPRAGUE DAWLEY RAT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; AUTOANTIBODIES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MYOGRAPHY; PROSPECTIVE STUDIES; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SCLERODERMA, SYSTEMIC;

EID: 84921348464     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201403-0442OC     Document Type: Article

References (37)

1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54(Suppl1):S43-S54.
2. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, et al.; ARIES-3 Study Group. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012;30:93-99.
3. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138:1383-1394.
4. Waxman AB, Zamanian RT. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Am J Cardiol 2013;111(Suppl5):1A-16A, quiz 17A-19A.
5. Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61:227-237.
6. Davie NJ, Schermuly RT, Weissmann N, Grimminger F, Ghofrani HA. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. Eur J Clin Invest 2009;39:38-49.
7. de Man FS, Handoko ML, Guignabert C, Bogaard HJ, Vonk-Noordegraaf A. Neurohormonal axis in patients with pulmonary arterial hypertension: friend or foe? Am J Respir Crit Care Med 2013;187:14-19.
8. de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, François C, Schalij I, Dorfmüller P, Simonneau G, Fadel E, et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:780-789.
9. Xie L, Lin P, Xie H, Xu C. Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats. Clin Exp Hypertens 2010;32:547-554.
10. El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012;55:218-228.
11. Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H, Matucci-Cerinic M, Czirják L, Lukitsch I, Becker M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011;70:530-536.
12. Kill A, Tabeling C, Undeutsch R, Kühl AA, Günther J, Radic M, Becker MO, Heidecke H, Worm M, Witzenrath M, et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 2014;16:R29.
13. Günther J, Kill A, Becker MO, Heidecke H, Rademacher J, Siegert E, Radić M, Burmester GR, Dragun D, Riemekasten G. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 2014;16:R65.
14. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005;352:558-569.
15. Becker M, Kill A, Undeutsch R, Tabeling C, Witzenrath M, Kuebler W, Bock S, Sampati R, Heidecke H, Ghofrani H, et al. Pathogenic effects of autoantibodies against vascular receptors in patients with SSc [abstract]. Rheumatology 2012;51 (Suppl 2):1-123.
16. Becker M, Kill A, Kutsche M, Günther J, Rose A, Tabeling C, Witzenrath M, Kühl A, Heidecke H, Ghofrani H, et al. Autoantibodies targeting angiotensin type 1 and endothelin type A receptors as biomarkers and mediators of systemic sclerosis associated pulmonary arterial hypertension [abstract]. Clin Exp Rheumatol 2014;32:23-54.
17. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, et al. 2013 classification criteria for systemic sclerosis: an American college of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-1755.
18. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, et al.; The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004;25:2243-2278.
19. 2+ and permeability response to platelet-activating factor is mediated by acid sphingomyelinase and transient receptor potential classical 6. Am J Respir Crit Care Med 2012;185:160-170.
20. 2+ signaling and cytoskeletal reorganization. Circ Res 2010;106:1103-1116.
21. Kuebler WM, Parthasarathi K, Lindert J, Bhattacharya J. Real-time lung microscopy. J Appl Physiol (1985) 2007;102:1255-1264.
22. Lukitsch I, Kehr J, Chaykovska L, Wallukat G, Nieminen-Kelhä M, Batuman V, Dragun D, Gollasch M. Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 2012;94:8-13.
23. Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, et al. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum 2014;44:55-62.
24. Bussone G, Tamby MC, Calzas C, Kherbeck N, Sahbatou Y, Sanson C, Ghazal K, Dib H, Weksler BB, Broussard C, et al. IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis 2012;71:596-605.
25. Terrier B, Tamby MC, Camoin L, Guilpain P, Broussard C, Bussone G, Yaïci A, Hotellier F, Simonneau G, Guillevin L, et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;177:1128-1134.
26. Barnes PJ. Receptor heterodimerization: a new level of cross-talk. J Clin Invest 2006;116:1210-1212.
27. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032.
28. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, Hogaboam C, Taraseviciene-Stewart L, Voelkel NF, Rabinovitch M, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 2008;205:361-372.
29. Hesselstrand R, Wildt M, Ekmehag B, Wuttge DM, Scheja A. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol 2011;40:127-132.
30. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-157.
31. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, Gressin V, Guillevin L, Clerson P, Simonneau G, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011;63:3522-3530.
32. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, Mouthon L, Guillevin L, Meyer O, Ekindjian OG, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58:284-291.
33. Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, Müller-Ladner U, Pope JE, Vonk MC, Doelberg M, et al.; DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014;73:1340-1349.
34. Colvin KL, Dufva MJ, Delaney RP, Ivy DD, Stenmark KR, Yeager ME. Biomarkers for pediatric pulmonary arterial hypertension - a call to collaborate. Front Pediatr 2014;2:7.
35. Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006;130:182-189.
36. Giral M, Foucher Y, Dufay A, Van Huyen JP, Renaudin K, Moreau A, Philippe A, Hegner B, Dechend R, Heidecke H, et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant 2013;13:2567-2576.
37. Hiemann NE, Meyer R, Wellnhofer E, Schoenemann C, Heidecke H, Lachmann N, Hetzer R, Dragun D. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012; 94:919-924.